Effect of physician payment disclosure laws on prescribing

Archives of Internal Medicine

Volumn 172, Issue 10, 2012, Pages 819-821

  Pham Kanter, Genevieve ^a,b,c,d   Alexander, G Caleb ^e   Nair, Kavita ^c  

^a HARVARD UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DRUG MARKETING; HEALTH CARE COST; HUMAN; LEGAL ASPECT; MEDICAL FEE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL;

DATABASES, FACTUAL; DISCLOSURE; DRUG INDUSTRY; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; GIFT GIVING; HEALTH CARE REFORM; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; PHYSICIAN'S PRACTICE PATTERNS; QUALITY CONTROL; UNITED STATES;

EID: 84861665315     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.1210     Document Type: Article

References (6)

1. Pub L No. 111-148, 124 Stat 199.
2. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007;297(11):1216-1223. (Pubitemid 46469916)
3. Rosenthal E. I disclose . . . nothing. http://www.nytimes.com/2012/01/22/ sunday-review/hard-truths-about-disclosure.html. Accessed January 22, 2012.
4. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. 2nd ed. Belmont, CA: Wadsworth; 2002.
5. Cameron AC, Trivedi PK. Microeconometrics: Methods and Applications. New York, NY: Cambridge University Press; 2005.
6. http://www.census.gov/acs/www/. US Census Bureau Web site. Accessed November 30, 2011.